Javascript must be enabled to continue!
AI-Driven drug discovery: Accelerating the development of novel therapeutics in biopharmaceuticals
View through CrossRef
Artificial Intelligence (AI) has emerged as a transformative force in drug discovery, revolutionizing the biopharmaceutical industry's approach to developing novel therapeutics. This paper provides a comprehensive overview of AI-driven drug discovery, focusing on its applications in accelerating the development of innovative treatments. We examine the fundamental AI technologies employed in drug discovery, including machine learning algorithms, deep learning architectures, and natural language processing techniques. The paper analyzes the integration of AI across various stages of the drug discovery pipeline, from target identification to clinical trial design, highlighting significant improvements in efficiency and accuracy. We explore the impact of big data on AI-driven drug discovery, discussing the challenges and opportunities presented by multi-omics data integration, electronic health records mining, and the need for data standardization. The study also addresses ethical considerations and regulatory challenges associated with AI implementation in drug development. Finally, we present emerging trends and prospects for AI in biopharmaceuticals, emphasizing the importance of collaborative ecosystems and the potential for AI to revolutionize personalized medicine. This review synthesizes current research and industry practices, providing insights into the transformative potential of AI in drug discovery and the challenges that lie ahead in realizing its full potential.
Keywords: Artificial Intelligence, Drug Discovery, Biopharmaceuticals, Machine Learning.
Fair East Publishers
Title: AI-Driven drug discovery: Accelerating the development of novel therapeutics in biopharmaceuticals
Description:
Artificial Intelligence (AI) has emerged as a transformative force in drug discovery, revolutionizing the biopharmaceutical industry's approach to developing novel therapeutics.
This paper provides a comprehensive overview of AI-driven drug discovery, focusing on its applications in accelerating the development of innovative treatments.
We examine the fundamental AI technologies employed in drug discovery, including machine learning algorithms, deep learning architectures, and natural language processing techniques.
The paper analyzes the integration of AI across various stages of the drug discovery pipeline, from target identification to clinical trial design, highlighting significant improvements in efficiency and accuracy.
We explore the impact of big data on AI-driven drug discovery, discussing the challenges and opportunities presented by multi-omics data integration, electronic health records mining, and the need for data standardization.
The study also addresses ethical considerations and regulatory challenges associated with AI implementation in drug development.
Finally, we present emerging trends and prospects for AI in biopharmaceuticals, emphasizing the importance of collaborative ecosystems and the potential for AI to revolutionize personalized medicine.
This review synthesizes current research and industry practices, providing insights into the transformative potential of AI in drug discovery and the challenges that lie ahead in realizing its full potential.
Keywords: Artificial Intelligence, Drug Discovery, Biopharmaceuticals, Machine Learning.
Related Results
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
Abstract
Background
Epetraborole (EBO) is an orally available, bacterial leucyl transfer RNA synthetase inhibitor that concentra...
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
Abstract
Background
SUL-DUR is a β-lactam/β-lactamase inhibitor combination in development for the treatment of ABC infections, ...
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
Abstract
Background
Epetraborole (EBO), an orally available bacterial leucyl transfer RNA synthetase inhibitor with potent activ...
592. Impact of Elevated MIC Values on Echinocandin Pharmacokinetic-Pharmacodynamic (PK-PD) Candida glabrata Target Attainment (TA)
592. Impact of Elevated MIC Values on Echinocandin Pharmacokinetic-Pharmacodynamic (PK-PD) Candida glabrata Target Attainment (TA)
Abstract
Background
Given the increasing prevalence of non-albicans Candida species, including C. glabrata and C. auris, which h...
Selection of Injectable Drug Product Composition using Machine Learning Models (Preprint)
Selection of Injectable Drug Product Composition using Machine Learning Models (Preprint)
BACKGROUND
As of July 2020, a Web of Science search of “machine learning (ML)” nested within the search of “pharmacokinetics or pharmacodynamics” yielded over 100...
What are biopharmaceuticals?
What are biopharmaceuticals?
Throughout history, biopharmaceuticals have been essential in addressing health crises and enhancing human well-being. With advancements in genetic engineering, biotechnology, and ...
Biopharmaceuticals—Current Information and New Challenges
Biopharmaceuticals—Current Information and New Challenges
Biopharmaceuticals are medical drugs produced by means of biotechnology. In contrast with small-molecule (traditional) drugs, which are usually synthesized chemically, biopharmaceu...
PHARMACEUTICAL AND CLINICAL CHALLENGES OF BIOLOGICAL MEDICINES: ONGOING HURDLES FROM DRUG DEVELOPMENT TO THERAPEUTIC APPLICATIONS
PHARMACEUTICAL AND CLINICAL CHALLENGES OF BIOLOGICAL MEDICINES: ONGOING HURDLES FROM DRUG DEVELOPMENT TO THERAPEUTIC APPLICATIONS
Beyond conventional small drug molecules mostly of synthetic origin, clinical benefits have been well established by administering large complex biomolecules against different dise...

